NCT06244628View on ClinicalTrials.gov

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

PHASE3RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

December 31, 2025

Conditions

cGVHD

Interventions

DRUG

Iguratimod

Oral administration of Iguratimod, 25mg twice daily

Trial Locations (1)

221000

RECRUITING

Kailin Xu, Xuzhou

All Listed Sponsors

lead

Xuzhou Medical University

OTHER